Current Study
Haemochromatosis | FERROCLEAR
This study is testing a new medicine called vamifeport in adults with a genetic condition that causes the body to absorb too much iron. Participants are randomly given either vamifeport or a placebo (a look‑alike treatment), and neither they nor the researchers know which one they’re receiving. The main goal is to see whether vamifeport can reduce the amount of excess iron in the liver, measured using an MRI scan.
Study Status
Recruiting
Duration
12 months
Clinic Visits
15
Phone Check-ins
1
Study Overview
Location
Osborne Park
Phase
2
Study Duration
12 months
Main Entry Criteria
- Confirmed diagnosis of HFE-HH and evidence of iron overload.Â
Main Exclusion Criteria
Assessments
- Medical and family history, including medicines, vitamins, and herbal supplements you take Â
- Vital signs like blood pressure, temperature, and pulse rate Â
- Height, weight, waist circumference, and physical examination Â
- Blood draws and urine collection for laboratory testsÂ
- Electrocardiogram (ECG)Â
- Magnetic resonance Imaging (MRI)
- Questionnaires related to the study
At a Glance
Clinic Visits
15
Phone Calls
1
Duration
12 months